138 related articles for article (PubMed ID: 8613942)
1. Both dynorphin A(1-17) and [Des-Tyr1]dynorphin A(2-17) inhibit adenylyl cyclase activity in rat caudate putamen.
Claye LH; Unterwald EM; Ho A; Kreek MJ
J Pharmacol Exp Ther; 1996 Apr; 277(1):359-65. PubMed ID: 8613942
[TBL] [Abstract][Full Text] [Related]
2. Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity.
Unterwald EM; Cox BM; Kreek MJ; Cote TE; Izenwasser S
Synapse; 1993 Sep; 15(1):33-8. PubMed ID: 8310423
[TBL] [Abstract][Full Text] [Related]
3. Dynorphin-selective inhibition of adenylyl cyclase in guinea pig cerebellum membranes.
Konkoy CS; Childers SR
Mol Pharmacol; 1989 Oct; 36(4):627-33. PubMed ID: 2572962
[TBL] [Abstract][Full Text] [Related]
4. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
Vig BS; Zheng MQ; Murray TF; Aldrich JV
J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
[TBL] [Abstract][Full Text] [Related]
5. Nonopioid motor effects of dynorphin A and related peptides: structure dependence and role of the N-methyl-D-aspartate receptor.
Shukla VK; Prasad JA; Lemaire S
J Pharmacol Exp Ther; 1997 Nov; 283(2):604-10. PubMed ID: 9353375
[TBL] [Abstract][Full Text] [Related]
6. Dynorphin regulates the phagocytic activity of splenic phagocytes in wall lizards: involvement of a κ-opioid receptor-coupled adenylate-cyclase-cAMP-PKA pathway.
Kumar S; Rai U
J Exp Biol; 2011 Dec; 214(Pt 24):4217-22. PubMed ID: 22116765
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
[TBL] [Abstract][Full Text] [Related]
8. Suppression by dynorphin A and [des-Tyr1]dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice.
Takemori AE; Loh HH; Lee NM
J Pharmacol Exp Ther; 1993 Jul; 266(1):121-4. PubMed ID: 8101214
[TBL] [Abstract][Full Text] [Related]
9. Neurological dysfunction after intrathecal injection of dynorphin A (1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory and autonomic function.
Long JB; Petras JM; Mobley WC; Holaday JW
J Pharmacol Exp Ther; 1988 Sep; 246(3):1167-74. PubMed ID: 2901487
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
Puttfarcken PS; Werling LL; Cox BM
Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
[TBL] [Abstract][Full Text] [Related]
12. Receptor preference of dynorphin A fragments in the mouse vas deferens determined by different techniques.
Schulz R; Wüster M; Herz A
J Pharmacol Exp Ther; 1984 Jul; 230(1):200-4. PubMed ID: 6146706
[TBL] [Abstract][Full Text] [Related]
13. Cocaine alters mu but not delta or kappa opioid receptor-stimulated in situ [35S]GTPgammaS binding in rat brain.
Schroeder JA; Niculescu M; Unterwald EM
Synapse; 2003 Jan; 47(1):26-32. PubMed ID: 12422370
[TBL] [Abstract][Full Text] [Related]
14. The role of dopaminergic systems in opioid receptor desensitization in nucleus accumbens and caudate putamen of rat after chronic morphine treatment.
Noble F; Cox BM
J Pharmacol Exp Ther; 1997 Nov; 283(2):557-65. PubMed ID: 9353370
[TBL] [Abstract][Full Text] [Related]
15. BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells.
Childers SR; Fleming LM; Selley DE; McNutt RW; Chang KJ
Mol Pharmacol; 1993 Oct; 44(4):827-34. PubMed ID: 8232233
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
Choi H; Murray TF; DeLander GE; Schmidt WK; Aldrich JV
J Med Chem; 1997 Aug; 40(17):2733-9. PubMed ID: 9276018
[TBL] [Abstract][Full Text] [Related]
17. Characterization of non-opioid [3H]dynorphin A-(1-13) binding sites in the rat heart.
Dumont M; Lemaire S
J Mol Cell Cardiol; 1993 Aug; 25(8):983-91. PubMed ID: 7903402
[TBL] [Abstract][Full Text] [Related]
18. [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist.
Patkar KA; Yan X; Murray TF; Aldrich JV
J Med Chem; 2005 Jul; 48(14):4500-3. PubMed ID: 15999987
[TBL] [Abstract][Full Text] [Related]
19. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
[TBL] [Abstract][Full Text] [Related]
20. Protection against dynorphin-(1-8) hydrolysis in membrane preparations by the combination of amastatin, captopril and phosphoramidon.
Hiranuma T; Kitamura K; Taniguchi T; Kanai M; Arai Y; Iwao K; Oka T
J Pharmacol Exp Ther; 1998 Aug; 286(2):863-9. PubMed ID: 9694943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
